AstraZeneca

Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More

While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t that long ago that another company’s gaze was fixed on the Summit, NJ, drug maker.

In the early 2000s, before the FDA approved Celgene’s flagship multiple myeloma drug lenalidomide (Revlimid), Novartis (NYSE: NVS considered buying the company. It passed, unwilling to risk billions on an unapproved drug. Those details came from biopharma dealmaker George Golumbeski, who was profiled in Xconomy this week. Golumbeski rose through the ranks to top positions at both companies, eventually earning a reputation for… Read more »

UNDERWRITERS AND PARTNERS

          

          

            
https://xconomy.com/national/2019/03/15/bio-roundup-golumbeskis-legacy-crispr-moratorium-rebate-week-more/

Advertisements
READ  Roivant takes aim at resistant infections with $667.5M Intron deal

Leave a Reply